Medlior presented exciting new results from a network meta-analysis (NMA) project sponsored by Pfizer Inc., at the Virtual ISPOR 2020 Annual Meeting. This poster presentation compared the effects of first-line treatments for non-small cell lung (NSCLC). A brief overview of the presentation is provided below – click HERE for the accompanying abstract and poster presentation.

Lung cancer is one of the most common cancers diagnosed, with 2.1 million cases reported globally in 2018. There are two main types of lung cancer, small cell lung cancer (SCLC) and NSCLC. Approximately 85% of lung cancers are NSCLC and of those, more than half are diagnosed with advanced (e.g., metastatic) disease. For those who have epidermal growth factor receptor mutation (EGFR+) NSCLC, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the initial course of treatment.

Medlior conducted a systematic literature review and NMA to identify and compare clinical trials (e.g., RCTs) that examined the effect of EGFR-TKIs on overall survival in patients with EGFR+ NSCLC.

Our search identified five RCTs that examined EGFR-TKIs in patients with EGFR+ NSCLC. From the NMA, dacomitinib (an EGFR-TKI therapy developed by Pfizer Inc.) showed numerical improvement in overall survival when compared to the other EGFR-TKI therapies examined (afatinib, erlotinib, gefitinib, osimertinib).

Overall, we found that dacomitinib should be considered as one of the standard treatment options for patients diagnosed with EGFR+ NSCLC.

The abstract was published in the Value and Health May 2020 issue and the poster will be included in the ISPOR Presentations Database. The ISPOR presentation updates the results from our prior publication in Future Oncology. Read more of our studies here.